Target intelligence / Profile preview

Killer cell immunoglobulin-like receptor, two Ig domains and short cytoplasmic tail 2 (KIR2DS2)

Target
KIR2DS2
Molecular classification
Receptor, Immunoglobulin superfamily, Type I transmembrane protein
01

Overview

Killer cell immunoglobulin-like receptor, two Ig domains and short cytoplasmic tail 2 (KIR2DS2) is a member of the KIR gene family, encoding a type I transmembrane glycoprotein found on the surface of natural killer (NK) cells and some T cells[1][3]. KIR2DS2 is classified as an activating receptor (short cytoplasmic tail), lacking ITIM motifs and instead signaling through adaptor proteins to activate NK cells[1]. It features two extracellular immunoglobulin-like domains. KIR2DS2 specifically recognizes subsets of HLA class I molecules, particularly HLA-A*11:01, and its interaction with HLA is influenced by the peptide presented and certain key residues[2]. The KIR2DS2/HLA interaction regulates innate immune responses, contributing to pathogen immunity and, in some contexts, to cancer surveillance and autoimmunity. High polymorphism and complex gene copy number variation characterize this family, adding to the variable expression and function of KIR2DS2 in different individuals[1][3]. If you need more specific clinical or drug development information related to KIR2DS2, please clarify the therapeutic area of interest.

Other names
CD158j (occasional)KI2S2 (UniProt)Killer cell Ig-like receptor 2DS2KIR2DS2 gene
02

Mechanism of action

Modulating KIR2DS2 could affect NK cell activation by altering recognition of HLA ligands, leading to increased or decreased cytotoxic activity

03

Biological functions

Immune responseInnate immunitySignal transduction in natural killer (NK) cells
04

Disease associations

InfectionCancerInflammationAutoimmune disease (association evidence, but less direct than infection)
05

Safety considerations

Potential for unwanted immune activation (off-target cytotoxicity, autoimmunity)Complex genetic variation complicates targeting and patient stratification
06

Biomarkers

HLA-A*11:01 (ligand with structural relevance)KIR2DS2 expression as possible stratification marker in NK cell-based therapies (investigational)

Beyond the preview

Go deeper on Killer cell immunoglobulin-like receptor, two Ig domains and short cytoplasmic tail 2 (KIR2DS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Killer cell immunoglobulin-like receptor, two Ig domains and short cytoplasmic tail 2 (KIR2DS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call